These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 8817647)

  • 1. Effect of the new HMG-CoA reductase inhibitor cerivastatin (BAY W 6228)on migration, proliferation and cholesterol synthesis in arterial myocytes.
    Corsini A; Arnaboldi L; Raiteri M; Quarato P; Faggiotto A; Paoletti R; Fumagalli R
    Pharmacol Res; 1996 Jan; 33(1):55-61. PubMed ID: 8817647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase.
    Corsini A; Mazzotti M; Raiteri M; Soma MR; Gabbiani G; Fumagalli R; Paoletti R
    Atherosclerosis; 1993 Jun; 101(1):117-25. PubMed ID: 8216498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pleiotropic effects of statins in atherosclerosis and diabetes.
    Bellosta S; Ferri N; Arnaboldi L; Bernini F; Paoletti R; Corsini A
    Diabetes Care; 2000 Apr; 23 Suppl 2():B72-8. PubMed ID: 10860194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-lipid-related effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
    Corsini A; Bernini F; Quarato P; Donetti E; Bellosta S; Fumagalli R; Paoletti R; Soma VM
    Cardiology; 1996; 87(6):458-68. PubMed ID: 8904671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct vascular effects of HMG-CoA reductase inhibitors.
    Bellosta S; Bernini F; Ferri N; Quarato P; Canavesi M; Arnaboldi L; Fumagalli R; Paoletti R; Corsini A
    Atherosclerosis; 1998 Apr; 137 Suppl():S101-9. PubMed ID: 9694549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacological control of biosynthesis pathway of mevalonate: effect on the proliferation of arterial smooth muscle cells].
    Corsini A; Arnaboldi L; Quarato P; Ferri N; Granata A; Fumagalli R; Paoletti R
    C R Seances Soc Biol Fil; 1997; 191(2):169-94. PubMed ID: 9255346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of neointimal thickening by a newly developed HMG-CoA reductase inhibitor, BAYw6228, and its inhibitory effect on vascular smooth muscle cell growth.
    Igarashi M; Takeda Y; Mori S; Ishibashi N; Komatsu E; Takahashi K; Fuse T; Yamamura M; Kubo K; Sugiyama Y; Saito Y
    Br J Pharmacol; 1997 Mar; 120(6):1172-8. PubMed ID: 9134232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogenesis of atherosclerosis and the role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
    Corsini A; Raiteri M; Soma MR; Bernini F; Fumagalli R; Paoletti R
    Am J Cardiol; 1995 Jul; 76(2):21A-28A. PubMed ID: 7604791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of cerivastatin on human arterial smooth muscle cell proliferation and migration in transfilter cocultures.
    Axel DI; Riessen R; Runge H; Viebahn R; Karsch KR
    J Cardiovasc Pharmacol; 2000 Apr; 35(4):619-29. PubMed ID: 10774794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HMG-CoA reductase inhibition reduces the proinflammatory activation of human vascular smooth muscle cells by the terminal complement factor C5b-9.
    Viedt C; Shen W; Fei J; Kamimura M; Hänsch GM; Katus HA; Kreuzer J
    Basic Res Cardiol; 2003 Nov; 98(6):353-61. PubMed ID: 14556080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HMG-CoA reductase inhibition improves endothelial cell function and inhibits smooth muscle cell proliferation in human saphenous veins.
    Yang Z; Kozai T; van der Loo B; Viswambharan H; Lachat M; Turina MI; Malinski T; Lüscher TF
    J Am Coll Cardiol; 2000 Nov; 36(5):1691-7. PubMed ID: 11079678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological control of the mevalonate pathway: effect on arterial smooth muscle cell proliferation.
    Raiteri M; Arnaboldi L; McGeady P; Gelb MH; Verri D; Tagliabue C; Quarato P; Ferraboschi P; Santaniello E; Paoletti R; Fumagalli R; Corsini A
    J Pharmacol Exp Ther; 1997 Jun; 281(3):1144-53. PubMed ID: 9190847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro.
    Flint OP; Masters BA; Gregg RE; Durham SK
    Toxicol Appl Pharmacol; 1997 Jul; 145(1):91-8. PubMed ID: 9221828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of HMG-CoA reductase inhibition on PDGF- and angiotensin II- mediated signal transduction: suppression of c-Jun and c-Fos in human smooth muscle cells in vitro.
    Kreuzer J; Watson L; Herdegen T; Loebe M; Wende P; Kübler K
    Eur J Med Res; 1999 Apr; 4(4):135-43. PubMed ID: 10205288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability.
    Koh KK
    Cardiovasc Res; 2000 Sep; 47(4):648-57. PubMed ID: 10974215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simvastatin but not pravastatin inhibits the proliferation of rat aorta myocytes.
    Corsini A; Raiteri M; Soma M; Fumagalli R; Paoletti R
    Pharmacol Res; 1991 Feb; 23(2):173-80. PubMed ID: 1905808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ajoene, a garlic compound, inhibits protein prenylation and arterial smooth muscle cell proliferation.
    Ferri N; Yokoyama K; Sadilek M; Paoletti R; Apitz-Castro R; Gelb MH; Corsini A
    Br J Pharmacol; 2003 Mar; 138(5):811-8. PubMed ID: 12642382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carvastatin suppresses intimal thickening of rabbit carotid artery after balloon catheter injury probably through the inhibition of vascular smooth muscle cell proliferation and migration.
    Komukai M; Wajima YS; Tashiro J; Shinomiya M; Saito Y; Morisaki N
    Scand J Clin Lab Invest; 1999 May; 59(3):159-66. PubMed ID: 10400160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Local statin therapy differentially interferes with smooth muscle and endothelial cell proliferation and reduces neointima on a drug-eluting stent platform.
    Jaschke B; Michaelis C; Milz S; Vogeser M; Mund T; Hengst L; Kastrati A; Schömig A; Wessely R
    Cardiovasc Res; 2005 Dec; 68(3):483-92. PubMed ID: 16111664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct vascular effects of HR780, a novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
    Wajima T; Makita S; Oshima K
    Clin Exp Pharmacol Physiol; 2003 Dec; 30(12):958-62. PubMed ID: 14678236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.